Navigation Links
Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
Date:1/12/2011

CHAPEL HILL, N.C., Jan. 12, 2011 /PRNewswire/ -- Cempra Pharmaceuticals presented the broad spectrum and potent activity profile of solithromycin (CEM-101), the first fluoroketolide antibiotic, at the 5th Annual PHEMCE stakeholders workshop and Biomedical Advanced Research and Development Authority (BARDA) industry day on January 10 to 12 in Washington D.C.  

Solithromycin is a clinical-stage fluoroketolide antibiotic with potent and broad-spectrum activity against gram-positive and gram-negative pathogens, including multidrug-resistant strains, non-bacterial pathogens such as Plasmodium falciparum and a variety of bio-defense pathogens including Bacillus anthracis, Yersinia pestis, Burkholderia mallei and Francisella tularensis.  Phase 1 clinical studies with the oral formulation have shown excellent safety and tolerability and a pharmacokinetic profile that will enable once-daily dosing.  The oral formulation is undergoing a Phase 2 clinical trial in patients with community-acquired bacterial pneumonia (CABP).  An intravenous (IV) formulation of solithromycin is undergoing a safety and tolerability evaluation in a Phase 1 single and multiple dose escalation trial in healthy volunteers.  An oral pediatric suspension is also under development.

The presentation, delivered on January 12 by Jennifer Schranz, M.D., vice president of clinical affairs at Cempra Pharmaceuticals, described the potential utility of solithromycin as a bio-defense agent due to its broad antimicrobial spectrum, safety and tolerability, once-daily dosing, high tissue penetration, intracellular accumulation, and compound stability.  Data from mouse models were presented on the activity of once-daily solithromycin compared to an optimal dosing regimen of ciprofloxacin against B. anthracis and gentamicin against F. tularensis.  Solithromycin demonstrated activity comparable to c
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
2. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
3. Savient Pharmaceuticals Provides Business Update
4. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Anadys Pharmaceuticals Augments Management Team and Board of Directors
6. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
7. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
9. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
10. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 2013 Cambridge Healthtech Institute will host ... 2013 at the Renaissance Waterfront Hotel in Boston, MA. ... close-up look at the current strategies and innovations for ... Leaders in the field will reveal how their ... with greater specificity and efficiency. , “In this age ...
(Date:5/16/2013)... 16, 2013  The registration deadline has been extended ... (ABFO) 2013 National Conference, the premier conference for bioscience ... at the Hilton San Diego Bayfront. ... conference and want to make sure as many people ... Brandi Roberts , Chief Financial Officer of ...
(Date:5/16/2013)... On average, developing a new drug takes ... Despite this investment, less than 10% of drugs make ... clinical trial design optimally structured to balance time, cost ... Frederic Sax, Global Head of the Center for Drug ... information and technology in upfront clinical trial planning and ...
(Date:5/16/2013)... May 16, 2013 BioInformatics LLC New ... & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) ... of suppliers in the primary cells market continues to ... types are used most often, how satisfied scientists are ... size and anticipated growth rate. ,  , Additionally, ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... Wash., Dec. 5 Nastech Pharmaceutical,Company Inc. (Nasdaq: ... a,feasibility study with an undisclosed global leader in the ... of Factor IX protein,which is currently administered by injection ... "We look forward to working with our new ...
... Mass., Dec. 4 A new, free ... Food and Drug Administration (FDA),regulations awaiting combination ... http://www.microtestlabs.com/combinationpaper ., While combination products ... and devices brings a host of regulatory,challenges. ...
... Solutions, LLC,Santa Clara, CA, a manufacturer of measurement ... the general release of its,TruBio(TM) IOQ package. TruBio(TM) ... validation and to complement the fully configurable TruBio(TM),operating ... systems can be expensive and time,consuming, especially when ...
Cached Biology Technology:Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding 2Free White Paper Addresses Challenges of New FDA Regulations Awaiting Combo Product Manufacturers 2Finesse Introduces TruBio(TM) IOQ 2
(Date:5/16/2013)... and the manager of San Diego Zoo Global,s Central ... award. The Whitley award is an international competition ... celebrates the extraordinary achievements of some of the world,s ... selected for the award due to his efforts to ... wildlife inhabitants., HRH The Princess Royal, the charity,s patron, ...
(Date:5/16/2013)... May 16, 2013 Reportlinker.com announces ... available in its catalogue: ... 2018 http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... security practises such as photographs, passwords and ... biometric technologies in last few years. Security ...
(Date:5/15/2013)... studies touting its benefit in moderating gout risk, new ... does not reduce uric acid (urate) levels to a ... C supplementation, alone or in combination with allopurinol, appears ... levels in gout patients according to the results published ... Arthritis & Rheumatism . , Gout is an ...
Breaking Biology News(10 mins):Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2
... Census of Marine Life explorers to the planet's most northern ... Ocean creatures, some believed new to science. , Sheltered for ... meters thick, unexpectedly high numbers and varieties of large Arctic ... in the extreme cold, thanks to a landmark voyage during ...
... of Cincinnati (UC) study provides new evidence that drinking ... and might explain why sweetening with fructose could be ... mice to freely consume either water, fructose sweetened water ... the mice that drank the fructose-sweetened water and soft ...
... mouse actually shrink during the winter, causing the mice to ... study found. , The results showed that, during the short ... mental map that helps them remember important places in their ... show seasonal changes in the structure and the functioning of ...
Cached Biology News:Census of Marine Life explorers surprised by diversity, density of Arctic creatures 2Census of Marine Life explorers surprised by diversity, density of Arctic creatures 3Census of Marine Life explorers surprised by diversity, density of Arctic creatures 4Census of Marine Life explorers surprised by diversity, density of Arctic creatures 5Research may provide new link between soft drinks and weight gain 2Mice brains shrink during winter, impairing some learning and memory 2Mice brains shrink during winter, impairing some learning and memory 3
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
CELLine System cultivation flask (for secreted products)...
... Microsphere/Microarray Stabilizer is an aqueous solution that ... non-toxic chemicals in a PBS buffer (phosphate ... This product contains a combination of 0.02% ... StabilCoat Plus Stabilizer provides optimum performance ...
... incubation trays are disposable trays ... antigens that have been blotted ... has eight 10.5 cm x ... strips cut from blotted membrane ...
Biology Products: